✨ Free AI Report
PharmaSGP Holding SE: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research PharmaSGP Holding SE
Company Research

PharmaSGP Holding SE: Business Overview, Financials & Competitive Analysis

PharmaSGP Holding SE is a Germany-based pharmaceutical company that produces and develops non-chemical and over-the-counter drugs and other healthcare products. The company specializes in natural, prescription-free ph...

Analyst-debate audio for PharmaSGP Holding SE

AskCyborg analysts argue the bull and bear cases for PharmaSGP Holding SE across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Growing German OTC pharma player with strong margins and profitable operations, benefiting from an aging demographic and...

Read the full analyst-debate transcript →
Industry Pharmaceutical Manufacturing - Over-the-Counter (OTC) Drugs & Specialty Generics
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest PharmaSGP Holding SE Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

PharmaSGP Holding SE Overview

Pro stress-test →

PharmaSGP Holding SE is a Germany-based pharmaceutical company that produces and develops non-chemical and over-the-counter drugs and other healthcare products. The company specializes in natural, prescription-free pharmaceuticals addressing chronic conditions, pain management, sleep disorders, and age-related ailments distributed through pharmacies and wholesalers across Germany and select European markets.

Strategic Profile

Pro stress-test →

The company achieved revenue of €118.84 million in 2024, representing 17.55% year-over-year growth. PharmaSGP maintains a focused portfolio of branded OTC products with strong market positioning in the German pharmacy channel, leveraging a lean operational structure with approximately 91 employees to deliver margins above 31% EBITDA.

Competitive Landscape

Pro stress-test →

PharmaSGP operates in the European OTC pharmaceutical market dominated by larger multinational players and specialized generic manufacturers. The company differentiates through its portfolio of branded natural and herbal formulations addressing underserved segments (sleep, sexual wellness, nerve pain) where it maintains relatively niche market positions. Key competitors include larger diversified pharma companies and regional specialty OTC players, though PharmaSGP's focused brand strategy and German market strength provide defensibility.

Industry Context

PharmaSGP Holding SE operates in Pharmaceutical Manufacturing - Over-the-Counter (OTC) Drugs & Specialty Generics.

Key facts

Founded: 2012 · Headquarters: Gräfelfing, Germany · Employees: 91 · Revenue: $118.84M (€) · Market cap: $324.65M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on PharmaSGP Holding SE.

  • Strong revenue growth momentum: 17.55% YoY increase in 2024 to €118.84M, with earnings up 19.14%
  • Exceptional operational efficiency with 31.32% EBITDA margins on a lean 91-employee base
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2024Revenue reached €118.84M, up 17.55% YoY with earnings of €19.54M (+19.14%)
  • 2025Analyst consensus 1-year price target of €39.50, implying significant upside from current levels
Get alerted when PharmaSGP Holding SE has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Aspirin and ibuprofen portfolioGlobal OTC pain relief and wellness products→Regional OTC pharmaceutical productsEuropean generic and OTC pharmaceutical manufacturer→Herbal and botanical remediesNatural medicine and homeopathic products→

Compare PharmaSGP Holding SE with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

PharmaSGP Holding SE operates in Pharmaceutical Manufacturing - Over-the-Counter (OTC) Drugs & Specialty Generics. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Manufacturing - Over-the-Counter (OTC) Drugs & Specialty Generics research →
NEW · MCP server

Ask your AI assistant about PharmaSGP Holding SE

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare PharmaSGP Holding SE and its top competitor on Cyborg Score”
“What did PharmaSGP Holding SE do this quarter?”
“Is PharmaSGP Holding SE a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does PharmaSGP Holding SE do?+
PharmaSGP Holding SE is a Germany-based pharmaceutical company that produces and develops non-chemical and over-the-counter drugs and other healthcare products. The company specializes in natural, prescription-free ph...
What is PharmaSGP Holding SE's Cyborg Score?+
PharmaSGP Holding SE has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are PharmaSGP Holding SE's main competitors?+
Named competitors include Aspirin and ibuprofen portfolio, Regional OTC pharmaceutical products, Herbal and botanical remedies. The full competitive landscape is in the AskCyborg report.
How can I get the full PharmaSGP Holding SE research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the PharmaSGP Holding SE research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track PharmaSGP Holding SE over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.